Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-11

Clinical Trial Update: A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of AR100DP1 in mild to moderate atopic dermatitis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AR100DP1

Snippet

Sponsor: Arjil Pharmaceuticals LLC | Conditions: Dermatitis, Atopic | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-12-11